Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.54 |
| ▸ | GRM5 | P41594 | 4/20 | 0.50 |
| ▸ | SPR | P35270 | 5/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073020 | 0.98 | HSD11B1 (0.51) | HSD11B1GRM5SPRUSP2CYP3A4 | |
| SCHEMBL15618729 | 0.93 | HSD11B1 (0.47) | HSD11B1GRM5SPRUSP2CYP3A4 | |
| SCHEMBL4072598 | 0.91 | GRM5 (0.59) | HSD11B1GRM5SPRUSP2CYP3A4 | |
| Hydrochloric Acid SCHEMBL30751767 | 0.91 | HSD11B1 (0.46) | HSD11B1GRM5SPRUSP2CYP3A4 | |
| SCHEMBL18422376 | 0.89 | GRM5 (0.49) | HSD11B1GRM5USP2CYP3A4CYP2C19 | |
| SCHEMBL22032412 | 0.89 | GRM5 (0.56) | HSD11B1GRM5SPRUSP2CYP3A4 | |
| SCHEMBL29418104 | 0.89 | HSD11B1 (0.42) | HSD11B1GRM5SPRUSP2CYP3A4 | |
| SCHEMBL4062010 | 0.86 | HSD11B1 (0.45) | HSD11B1GRM5SPRUSP2CYP3A4 | |
| SCHEMBL30329203 | 0.84 | GRM5 (0.52) | HSD11B1GRM5SPRUSP2CYP3A4 | |
| SCHEMBL4066092 | 0.84 | GRM5 (0.52) | HSD11B1GRM5SPRUSP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-05-08 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-111601807-B | Exo-azaspiro inhibitors of MENIN-MLL interactions | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-26 | — | — | US | disclosed |
| EP-2520568-A1 | Spirocyclic nitriles as inhibitors of protease | SANOFI (FR) | 2012-11-07 | — | — | EP | disclosed |
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| EP-2032535-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007137738-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | KRAS, HRAS, NRAS | HSD11B1 3145/4885GRM5 4554/4885SPR 3999/4885 |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | HSD11B1 2670/4885GRM5 1304/4885SPR 3098/4885 |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | KRAS, HRAS, NRAS | HSD11B1 3197/4885GRM5 4186/4885SPR 1900/4885 |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | BMI1, MLLT1, EED | HSD11B1 2531/4885GRM5 2427/4885SPR 1818/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | HSD11B1 3036/4885GRM5 4411/4885SPR 1005/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | HSD11B1 2299/4885GRM5 4524/4885SPR 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.